deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02481310

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen

Sponsor: Millennium Pharmaceuticals, Inc.

Conditions Adult Burkitt Lymphoma B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma Diffuse Large B-Cell Lymphoma MYC Gene Mutation Plasmablastic Lymphoma
Interventions Cyclophosphamide Cytarabine Doxorubicin Hydrochloride Etoposide Ixazomib Citrate Laboratory Biomarker Analysis Methotrexate Prednisone Rituximab Therapeutic Hydrocortisone Vincristine Sulfate
Updated 13 times since 2017 Last updated: Feb 17, 2022 Started: Oct 28, 2015 Primary completion: Sep 26, 2020 Completion: Jul 31, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Adult Burkitt Lymphoma and B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, this trial is ongoing. The trial is conducted by Millennium Pharmaceuticals, Inc. and has accumulated 13 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Apr 2020 · 17 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE1/PHASE2

  2. Aug 2024 — Sep 2024 [monthly]

    Unknown PHASE1/PHASE2

    Status: Active Not Recruiting → Unknown

  3. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Mar 2022 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jan 2022 — Mar 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 8 earlier versions

  1. Jan 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Apr 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Nov 2018 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

  4. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  6. Sep 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Feb 2017 — Sep 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Millennium Pharmaceuticals, Inc.
  • National Cancer Institute (NCI)
  • Northwestern University
Data source: Northwestern University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations